Company intelligence / Profile preview

Crossfire Oncology

Oss, North Brabant, Netherlandscrossfire-oncology.com ↗

Ownership: Private
Employees: ~13
Development stage: Other

Overview

BAL0891 is a dual PLK1/TTK inhibitor with demonstrated tumor growth suppression and survival benefit in animal models. It is being evaluated in Phase 2 clinical trials for both solid tumors and blood cancers. CFON‑026 is a best-in-class non-covalent macrocyclic BTK inhibitor active against wild-type and resistant BTK mutants; it is expected to enter clinical trials late 2025. The company’s proprietary EPriL platform enables rapid development of novel degraders and degrader antibody conjugates targeting kinases implicated in therapy resistance or poor response.

Therapeutic areas: Oncology
Modalities: Small moleculeDegrader-antibody conjugateChemical drugsAntibody-drug conjugate
Industry: Biotech

Drug pipeline

1 asset

CFON-026

Preclinical

Beyond the preview

Go deeper on Crossfire Oncology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Crossfire Oncology.

Explore the full profile